Abstract
Background: Fibrolamellar Carcinoma (FLC) and Combined Hepatocellular- Cholangiocarcinoma (CHC) are rare primary liver tumours, which are related to different clinical settings. In both tumours, correlation with clinical data and laboratory tests are extremely important.
Discussion: Typically, FLC is diagnosed in young patients without any chronic disease and with normal biochemical tests, whereas CHC arises in cirrhotic patients with elevated tumour markers: AFP and/or CA 19-9.
The review describes epidemiology, aetiology, pathogenesis, radiological features and treatment of these tumours.
Imaging features typical for FLC are: The presence of central scar, calcifications, the large size, heterogeneous and early contrast-enhancement.
Conclusion: The diagnosis of CHC may be suggested in case of elevation of both AFP and CA 19- 9 or inconsistency between elevated tumour markers and imaging findings (i.e., elevated CA 19-9 and radiological features of HCC, or elevated AFP with imaging findings characteristic of ICC).
Keywords: Fibrolamellar carcinoma, combined hepatocellular-cholangiocarcinoma, primary hepatic tumors, hepatobiliary contrast agents, computed tomography, magnetic resonance imaging.
Graphical Abstract
[1]
Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of the liver in infancy and childhood. Am J Dis Child 1956; 91(2): 168-86.
[2]
Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: A tumor of adolescents and young adults with distinctive clinicopathologic features. Cancer 1980; 46: 372-9.
[3]
Berman MA, Burnham JA, Sheahan DG. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol 1988; 19(7): 784-94.
[4]
Terzis I, Haritanti A, Economou I. Fibrolamellar hepatocellular carcinoma: A case report with distinct radiological features. J Gastrointest Cancer 2010; 41(1): 2-5.
[5]
Liu S, Wah Chan K, Tong J, Wang Y, Wang B, Qiao L. PET-CT scan is a valuable modality in the diagnosis of fibrolamellar hepatocellular carcinoma: A case report and a summary of recent literature. QJM 2011; 104(6): 477-83.
[6]
Sooklim K, Sriplung H, Piratvisuth T. Histologic subtypes of hepatocellular carcinoma in the southern Thai population. Asian Pac J Cancer Prev 2003; 4(4): 302-6.
[7]
El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A U.S. population-based study. Hepatology 2004; 39(3): 798-803.
[8]
Liu S, Chan KW, Wang B, Qiao L. Fibrolamellar hepatocellular carcinoma. Am J Gastroenterol 2009; 104(10): 2617-24.
[9]
Górnicka B, Ziarkiewicz-Wróblewska B, Wróblewski T, et al. Carcinoma, a fibrolamellar variant - immunohistochemical analysis of 4 cases. Hepatogastroenterology 2005; 52: 519-23.
[10]
Arista-Nasr J, Gutierrez-Villalobos L, Nuncio J, Maldonaldo H, Bornstein-Quevedo L. Fibrolamellar hepatocellular carcinoma in Mexican patients. Pathol Oncol Res 2002; 8(2): 133-7.
[11]
Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol 2007; 14(3): 217-23.
[12]
Meriggi F, Forni E. Surgical therapy of hepatic fibrolamellar carcinoma. Ann Ital Chir 2007; 78(1): 53-8.
[13]
Ichikawa T, Federle MP, Grazioli L, Madariaga J, Nalesnik M, Marsh W. Fibrolamellar hepatocellular carcinoma: Imaging and pathologic findings in 31 recent cases. Radiology 1999; 213(2): 352-61.
[14]
McLarney JK, Rucker PT, Bender GN, Goodman ZD, Kshitani N, Ros PR. Fibrolamellar carcinoma of the liver: Radiologicpathologic correlation. Radiographics 1999; 19(2): 453-71.
[15]
Ganeshan D, Szklaruk J, Kundra V, Kaseb A, Rashid A, Elsayes KM. Imaging features of fibrolamellar hepatocellular carcinoma. AJR Am J Roentgenol 2014; 202(3): 544-52.
[16]
Tanaka K, Honna T, Kitano Y, et al. Combined fibrolamellar carcinoma and cholangiocarcinoma exhibiting biphenotypic antigen expression: A case report. J Clin Pathol 2005; 58(8): 884-7.
[17]
Malouf GG, Brugieres L, Le Deley MC, et al. Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection. Cancer 2012; 118(20): 4981-90.
[18]
Khoo JJ, Clouston A. Fibrolamellar hepatocellular carcinoma: A case report. Malays J Pathol 2001; 23(2): 115-8.
[19]
Kassahun WT. Contemporary management of fibrolamellar hepatocellular carcinoma: Diagnosis, treatment, outcome, prognostic factors, and recent developments. World J Surg Oncol 2016; 14(1): 151.
[20]
Do RK, McErlean A, Ang CS, DeMatteo RP, Abou-Alfa GK. CT and MRI of primary and metastatic fibrolamellar carcinoma: A case series of 37 patients. Br J Radiol 2014; 87(1040): 20140024.
[21]
Kakar S, Burgart LJ, Batts KP, Garcia J, Jain D, Ferrell LD. Clinicopathologic features and survival in fibrolamellar carcinoma: Comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol 2005; 18(11): 1417-23.
[22]
Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer 2003; 97(8): 2006-12.
[23]
Ichikawa T, Federle MP, Grazioli L, Marsh W. Fibrolamellar hepatocellular carcinoma: Pre- and posttherapy evaluation with CT and MR imaging. Radiology 2000; 217(1): 145-51.
[24]
Stipa F, Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer 2006; 106(6): 1331-8.
[25]
Sarode VR, Castellani R, Post A. Fine-needle aspiration cytology and differential diagnoses of fibrolamellar hepatocellular carcinoma metastatic to the mediastinum: case report. Diagn Cytopathol 2002; 26(2): 95-8.
[26]
Montero A, Allende H, Tallada N, Ramon y Cajal S, Margarit C, Viladomiu L. Fine needle aspiration cytology of massive bilateral ovarian metastasis of fibrolamellar hepatocellular carcinoma. Acta Cytol 2007; 51(4): 682-3.
[27]
Kutluk MT, Yalçin B, Büyükpamukçu N, et al. Fibrolamellar hepatocellular carcinoma with skeletal metastases. Pediatr Hematol Oncol 2001; 18(4): 273-8.
[28]
Mavros MN, Mayo SC, Hyder O, Pawlik TM. A systematic review: Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg 2012; 215(6): 820-30.
[29]
Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. 4th ed. Vol.3, Lyon 2010.
[30]
Blachar A, Federle MP, Ferris JV, et al. Radiologists’ performance in the diagnosis of liver tumors with central scars by using specific CT criteria. Radiology 2002; 223(2): 532-9.
[31]
Ichikawa T, Federle MP, Grazioli L, Marsh W. Fibrolamellar hepatocellular carcinoma: Pre- and posttherapy evaluation with CT and MR imaging. Radiology 2000; 217(1): 145-51.
[32]
Pedrassa BC, da Rocha EL, Kierszenbaum ML, et al. Uncommon hepatic tumors: Iconographic essay-Part 1. Radiol Bras 2014; 47(5): 310-6.
[33]
De Gaetano AM, Nure E, Grossi U, et al. Fibrolamellar hepatocellular carcinoma with biliary tumor thrombus: An unreported association. Jpn J Radiol 2013; 31(10): 706-12.
[34]
McLarney JK, Rucker PT, Bender GN, Goodman ZD, Kshitani N, Ros PR. Fibrolamellar carcinoma of the liver: Radiologic-pathologic correlation. Radiographics 1999; 19(2): 453-71.
[35]
Liu S, Wah Chan K, Tong J, Wang Y, Wang B, Qiao L. PET-CT scan is a valuable modality in the diagnosis of fibrolamellar hepatocellular carcinoma: A case report and a summary of recent literature. QJM 2011; 104(6): 477-83.
[36]
von Falck C, Rodt T, Shin HO, Knapp WH, Galanski M. F-18 FDG PET imaging of fibrolamellar hepatocellular carcinoma. Clin Nucl Med 2008; 33(9): 633-4.
[37]
Campos JT, Sirlin CB, Choi JY. Focal hepatic lesions in Gd-EOB-DTPA enhanced MRI: The atlas. Insights Imaging 2012; 3(5): 451-74.
[38]
Ringe KI, Husarik DB, Sirlin CB, Merkle EM. Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 2010; 195(1): 13-28.
[39]
Park MJ, Kim YK, Park HJ, Hwang J, Lee WJ. Scirrhous hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging and diffusion-weighted imaging: Emphasis on the differentiation of intrahepatic cholangiocarcinoma. J Comput Assist Tomogr 2013; 37(6): 872-81.
[40]
Brancatelli G, Federle MP, Grazioli L, Blachar A, Peterson MS, Thaete FL. Focal nodular hyperplasia: CT findings with emphasis on multiphasic helical CT in 78 patients. Radiology 2001; 219(1): 61-8.
[41]
Vilgrain V, Boulos L, Vullierme MP, Denys A, Terris B, Menu Y. Imaging of atypical hemangiomas of the liver with pathologic correlation. Radiographics 2000; 20(2): 379-97.
[42]
Rousseau C, Ronot M, Sibileau E, et al. Central element in liver masses, helpful, or pitfall? Abdom Imaging 2015; 40(6): 1904-25.
[43]
Shetty AS, Fowler KJ, Brunt EM, Agarwal S, Narra VR, Menias CO. Combined hepatocellular-cholangiocarcinoma: what the radiologist needs to know about biphenotypic liver carcinoma. Abdom Imaging 2014; 39(2): 310-22.
[44]
Maximin S, Ganeshan DM, Shanbhogue AK, et al. Current update on combined hepatocellular-cholangiocarcinoma. Eur J Radiol Open 2014; 1: 40-8.
[45]
Willekens I, Hoorens A, Geers C, Op de Beeck B, Vandenbroucke F, de Mey J. Combined hepatocellular and cholangiocellular carcinoma presenting with radiological characteristics of focal nodular hyperplasia. World J Gastroenterol 2009; 15(31): 3940-3.
[46]
Yin X, Zhang BH, Qiu SJ, et al. Combined hepatocellular carcinoma and cholangiocarcinoma: Clinical features, treatment modalities, and prognosis. Ann Surg Oncol 2012; 19(9): 2869-76.
[47]
Lin G, Toh CH, Wu RC, et al. Combined hepatocellular cholangiocarcinoma: Prognostic factors investigated by computed tomography/magnetic resonance imaging. Int J Clin Pract 2008; 62(8): 1199-205.
[48]
de Campos RO, Semelka RC, Azevedo RM, et al. Combined hepatocellular carcinoma-cholangiocarcinoma: Report of MR appearance in eleven patients. J Magn Reson Imaging 2012; 36(5): 1139-47.
[49]
Nayyar M, Imagawa DK, Tirkes T, et al. Composite liver tumors: A radiologic-pathologic correlation. Clin Mol Hepatol 2014; 20(4): 406-10.
[50]
Fowler KJ, Sheybani A, Parker RA III, et al. Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: Imaging features and diagnostic accuracy of contrast-enhanced CT and MRI. AJR Am J Roentgenol 2013; 201(2): 332-9.
[51]
Hwang J, Kim YK, Park MJ, et al. Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI. J Magn Reson Imaging 2012; 36(4): 8.
[52]
Schiettecatte A, Dujardin M, de Beeck BO, de Mey J. Combined hepatocellular-cholangiocarcinoma: MR findings. European Journal of Radiology Extra 2008; 67: 75-7.
[53]
Zhou YM, Yang JM, Wang B, Xu F, Tong Y, Li DQ. Combined hepatocellular carcinoma and cholangiocarcinoma: A case report and review of the literature. Hepatobiliary Pancreat Dis Int 2007; 6(6): 656-9.
[54]
Nishie A, Yoshimitsu K, Asayama Y, et al. Detection of combined hepatocellular and cholangiocarcinomas on enhanced CT: Comparison with histologic findings. AJR Am J Roentgenol 2005; 184(4): 1157-62.
[55]
Joo I, Kim H, Lee JM. Cancer Stem cells in primary liver cancers: Pathological concepts and imaging findings. Korean J Radiol 2015; 16(1): 50-68.
[56]
Meriggi F, Forni E. Surgical therapy of hepatic fibrolamellar carcinoma. Ann Ital Chir 2007; 78(1): 53-8.
[57]
Jarnagin WR, Weber S, Tickoo SK, et al. Combined hepatocellular and cholangiocarcinoma: Demographic, clinical, and prognostic factors. Cancer 2002; 94(7): 2040-6.
[58]
Yano Y, Yamamoto J, Kosuge T, et al. Combined hepatocellular and cholangiocarcinoma: A clinicopathologic study of 26 resected cases. Jpn J Clin Oncol 2003; 33(6): 283-7.
[59]
Zhou YM, Zhang XF, Wu LP, Sui CJ, Yang JM. Risk factors for combined hepatocellular-cholangiocarcinoma: A hospital-based case-control study. World J Gastroenterol 2014; 20(35): 12615-20.
[60]
Theise ND, Yao JL, Harada K, et al. Hepatic ‘stem cell’ malignancies in adults: Four cases. Histopathology 2003; 43(3): 263-71.
[61]
Koh KC, Lee H, Choi M, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg 2005; 189(1): 120-5.
[62]
Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N. Combined hepatocellular and cholangiocarcinoma: Clinical features and prognostic study in a Thai population. J Hepatobiliary Pancreat Surg 2006; 13(6): 537-42.
[63]
Kassahun WT, Hauss J. Management of combined hepatocellular and cholangiocarcinoma. Int J Clin Pract 2008; 62(8): 1271-8.
[64]
Toh CH, Cheung YC, Ng SH, Lin CY, Chan SC, Ng KK. Combined hepatocellular-cholangiocarcinoma: A case report. Int J Clin Pract 2004; 58(12): 1170-3.
[65]
Lee CC, Wu CY, Chen JT, Chen GH. Comparing combined hepatocellular-cholangiocarcinoma and cholangiocarcinoma: A clinicopathological study. Hepatogastroenterology 2002; 49(48): 1487-90.
[66]
Tang D, Nagano H, Nakamura M, et al. Clinical and pathological features of Allen’s type C classification of resected combined hepatocellular carcinoma and cholangiocarcinoma: A comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg 2006; 10(7): 987-98.
[67]
Sanada Y, Shiozaki S, Aoki H, Takakura N, Yoshida K, Yamaguchi Y. A clinical study of 11 cases of combined hepatocellular-cholangiocarcinoma Assessment of Enhancement patterns on dynamics computed tomography before resection. Hepatol Res 2005; 32(3): 185-95.
[68]
Aoki K, Takayasu K, Kawano T, et al. Combined hepatocellular carcinoma and cholangiocarcinoma: Clinical features and computed tomographic findings. Hepatology 1993; 18(5): 1090-5.
[69]
Shin CI, Lee JM, Kim SH, et al. Recurrence patterns of combined hepatocellular-cholangiocarcinoma on enhanced computed tomography. J Comput Assist Tomogr 2007; 31(1): 109-15.
[70]
Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005; 234(2): 468-78.
[71]
Liu CL, Fan ST, Lo CM, et al. Hepatic resection for combined hepatocellular and cholangiocarcinoma. Arch Surg 2003; 138(1): 86-90.
[72]
Panjala C, Senecal DL, Bridges MD, et al. The diagnostic conundrum and liver transplantation outcome for combined hepatocellular- cholangiocarcinoma. Am J Transplant 2010; 10(5): 1263-7.
Article Metrics
37
2